RUNX3

Aliases
  • AML2
  • Acute myeloid leukemia 2 protein
  • CBF-alpha-3
  • CBFA3
  • Core-binding factor subunit alpha-3
  • Oncogene AML-2
  • PEA2-alpha C
  • PEBP2-alpha C
  • PEBP2A3
  • Polyomavirus enhancer-binding protein 2 alpha C subunit
  • RUNX3
  • Runt-related transcription factor 3
  • SL3-3 enhancer factor 1 alpha C subunit
  • SL3/AKV core-binding factor alpha C subunit
Description
RUNX3 is a member of the runt domain-containing family of transcription factors. A heterodimer of this protein and a beta subunit forms a complex that binds to the core DNA sequence 5'-PYGPYGGT-3' found in a number of enhancers and promoters, and can either activate or suppress transcription. It also interacts with other transcription factors. It functions as a tumor suppressor, and the gene is frequently deleted or transcriptionally silenced in cancer. Multiple transcript variants encoding different isoforms have been found for this gene.
Attributes
QA State
Accepted
Type
Genomic
HGNC Name
RUNX3
Certifications
  • None
QA State for Esophagus
Accepted
Organ-Specific Notes

Esophageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.

Performance Comment

p16, RUNX3, and TMEFF2 (HPP1) display increasing methylation frequencies in Barrett's esophagus versus esophageal adenocarcinoma. These markers are being further investigated for potential utility in screening Barrett's patients likely to develop esophageal adenocarcinoma.

Supporting Study Data
Barretts Esophagus Methylation Profiles
Study phase on the esophagus: 3

We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.

View Protocol
Decision rule: PMID:15824739
Barretts Esophagus Methylation Profiles
Study phase on the esophagus: 3

We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.

View Protocol
Decision rule: PMID:15824739
Esophagus-Specific Protocols
  • No organ-level protocols specified for esophagus.
Esophagus-Specific Publications
  • No organ-level publications were listed for esophagus.
Esophagus-Specific Resources
  • No organ-level resources were given for esophagus.
Certifications
  • None
QA State for Lung
Under Review

 Non-Public Biomarker

Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.